Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

"The Rise of Mannkind"

|Includes: MannKind Corporation (MNKD)

Mannkind Corporation, “MNKD”, currently has a drug, Afrezza, for the treatment of type 1 and type 2 diabetes in stage three trials. In addition to Afrezza, Mannkind has a number of other drugs for the treatment of cancer in its pipeline that have shown great potential in early stage testing.

On Friday, June 24, Mannkind released the results of two studies regarding Afrezza that are of great significance in that they relate to two areas that the F.D.A. seems to focus on when deciding on drug approval.


Information on the two studies is as follows:

Studies Show No Increased Risk of Cardiac Events in Diabetes Patients Treated with AFREZZA®

Type 1 Diabetes Patients Using AFREZZA Have More Positive View of Therapy Compared to Standard Insulin Therapy

For an excellent overview of the current situation with Mannkind take the time to listen to the following webcast of Mannkind’s presentation at the Wells Fargo Securities Healthcare Conference on Thursday, June 23, 2011 11:15 a.m. ET

Important Comment(s) from the Presentation:

16:50 Mark:   Summary: FDA suggested obtaining approval for both type 1 and type 2 diabetes to address the entire market. Enormously increases the market. Discussions with potential partners have become substantially more interesting.

20:30 Mark:    Currently in discussions with potential partners for the oncology drugs.

Big pharma companies are currently facing the loss of over $100 billion in revenues over the next three years with drugs going “off patent”. Mannkind is one of the few companies that has a potential “blockbuster” drug in late stage development that is a realistic target for a partnership or as a takeover target.

“Increasing M & A Activity Due To Big Pharma Patent Cliff”

With almost 23,000,000 shares short which represents about 37% of the float a partnership/buyout announcement could easily move the share price to the $15.00 range.

A recent rumor on suggested that Eli Lilly was readying a $12.50/share offer for Mannkind.

I think a realistic view of Mannkind’s future share price performance is best represented by Human Genome Sciences’ two year chart for the two year period since it signed a development partnership with Glaxo.

The following will provide you with a little insight about Mannkind’s billionaire C.E.O., Al Mann.

"Alfred E. Mann Awarded MDEA Lifetime Achievement Award”

Due diligence but do check out the opportunity that Mannkind’s share price appreciation offers. Do so before the first of multiple partnerships is announced and the share price gaps substantially higher.


The “rise of Mannkind” is closer than you think.